Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.
Sponsor: Shanghai 6th People's Hospital
This PHASE1/PHASE2 trial investigates Acute Cerebral Stroke Within 12 Hours for the First Time and is currently completed. Shanghai 6th People's Hospital leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai 6th People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .